SCHEMBL16321792

SCHEMBL16321792

O=c1cc(NC(c2ccccc2)C2CCC2)[nH]c(=O)n1CC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2B6 P20813 1/20 0.39
▸ CA1 P00915 1/20 0.35
▸ MDM2 Q00987 2/20 0.34
▸ SMYD3 Q9H7B4 1/20 0.33
▸ CCR6 P51684 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ S1PR1 P21453 1/20 0.32
▸ PDE2A O00408 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16321791 1.00 SMN1; SMN2 (0.40) SMN1; SMN2HTTCYP3A4CYP2B6CA1
SCHEMBL16341250 0.96 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP3A4CYP2B6SMYD3
SCHEMBL16341248 0.96 SMN1; SMN2 (0.41) SMN1; SMN2HTTCYP3A4CYP2B6SMYD3
SCHEMBL16324432 0.86 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6CA1
SCHEMBL16324434 0.86 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6CA1
SCHEMBL16320759 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTCYP3A4CYP2B6SMYD3
SCHEMBL16320758 0.81 SMN1; SMN2 (0.46) SMN1; SMN2HTTCYP3A4CYP2B6SMYD3
SCHEMBL16364693 0.80 SMN1; SMN2 (0.44) SMN1; SMN2HTTCYP3A4CYP2B6ALDH1A1
SCHEMBL16324209 0.80 SMN1; SMN2 (0.63) SMN1; SMN2HTTCYP3A4CYP2B6TP53
SCHEMBL16324210 0.80 SMN1; SMN2 (0.63) SMN1; SMN2HTTCYP3A4CYP2B6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744664-A2 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2026-05-20 — — EP disclosed
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2024-11-21 — — US disclosed
US-RE50050-E1 Pyrimidinedione compounds MyoKardia, Inc. (US) 2024-07-23 — — US disclosed
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 — — US disclosed
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 — — US disclosed
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2021-11-11 — — US disclosed
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2021-11-11 — — US disclosed
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2020-09-24 — — US disclosed
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2020-09-24 — — US disclosed
EP-3702352-A1 PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2020-09-02 — — EP disclosed
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2018-11-01 — — US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 — — US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 — — US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 — — US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 — — US disclosed
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2016-02-04 — — US disclosed
US-9181200-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2015-11-10 — — US disclosed
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2014-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD SMN1; SMN2 1177/4885HTT 286/4885CYP3A4 2600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback